Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 12/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3455166 | 0.93 | S1PR1 (0.57) | S1PR1S1PR4S1PR5S1PR3KCNH2 | |
| SCHEMBL20405969 | 0.91 | S1PR1 (0.50) | S1PR1S1PR4S1PR5S1PR3KCNH2 | |
| SCHEMBL3751169 | 0.91 | S1PR1 (0.49) | S1PR1S1PR4S1PR5S1PR3KCNH2 | |
| SCHEMBL3751157 | 0.88 | CYP2D6 (0.45) | S1PR1MAPK1 | |
| SCHEMBL10181621 | 0.88 | S1PR1 (0.49) | S1PR1S1PR4S1PR5S1PR3KCNH2 | |
| SCHEMBL13765382 | 0.87 | S1PR1 (0.47) | S1PR1S1PR4S1PR5S1PR3KCNH2 | |
| SCHEMBL3756948 | 0.87 | S1PR1 (0.45) | S1PR1KCNH2NPC1ALDH1A1MAPK1 | |
| SCHEMBL3755225 | 0.87 | POLB (0.42) | S1PR1S1PR4S1PR5S1PR3KCNH2 | |
| SCHEMBL3761101 | 0.87 | S1PR1 (0.41) | S1PR1S1PR4S1PR5S1PR3KCNH2 | |
| SCHEMBL3755464 | 0.86 | S1PR1 (0.41) | S1PR1S1PR4S1PR5S1PR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250165-B1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2018-07-25 | — | — | EP | disclosed |
| EP-2250165-B1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2018-07-25 | — | — | EP | disclosed |
| CN-101918395-B | Triazole oxadiazole derivatives | MERCK SERONO SA | 2014-04-16 | — | — | CN | disclosed |
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| CN-101918395-A | Triazole oxadiazole derivatives | MERCK SERONO SA | 2010-12-15 | — | — | CN | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| WO-2009080663-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | OXA1L, RO60, PDCD11 | S1PR1 517/4885S1PR4 733/4885S1PR5 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.